MUMBAI, India, March 8, 2018 /PRNewswire/ -- Commenting on this strategic alliance, Dr. Natarajan Ranganathan, Ph.D. (Bio-organic Chemistry), inventor of the globally patented product, and the Founder and Managing Director of Kibow Biotech, said, "As my roots are from India, I am extremely happy that my company Kibow Biotech has collaborated with Centaur Pharmaceuticals. Now we can together offer the benefits of my 20 years of research to millions of Indian patients suffering from Chronic Kidney Illness and make their lives better. Kibow also has an interesting research pipeline which we hope to bring to India for the benefit of Indian patients."
Speaking on this occasion, Mr. S. D. Sawant, Chairman and MD of Centaur Pharmaceuticals, said, "Kibow has a strong research infrastructure and expertise in modulating gut microbiome. Through this alliance, Centaur will leverage Kibow's research expertise and its own strong manufacturing and marketing skills to offer hope in the form of Renadyl to patients in India suffering from Chronic Kidney Illness. We are happy to announce this alliance in the backdrop of World Kidney Day and World Women's Day coming up on 8th March.
About Centaur Pharmaceuticals
Centaur Pharmaceuticals was founded in 1978 and today is one of the Top 50 pharmaceutical companies in India. It ranks amongst India's few, fully integrated pharmaceutical firms with proficiencies across API, R&D, CRAM, Clinical Research and formulations, and exports to 96 countries. Centaur has four manufacturing facilities, two of which are USFDA approved. Centaur markets Sinarest, India's No.1 anti-cold brand since 1996. Centaur has won the AWACS- Brand of the Year Award for Sinarest consecutively for the last four years.
About Kibow Biotech USA
Kibow Biotech is a biotechnology company founded in 1997, involved in cutting edge research of modulating the gut microbiome through innovative research products. Kibow has invented a globally patented product 'Renadyl™' for promoting kidney health. Other innovative products of Kibow include Azodyl®, Kibow Flora® and Kibow Fortis®.
 Singh AK, Farag YM, Mittal BV, et al. Epidemiology and risk factors of chronic kidney disease in India – results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC Nephrology. 2013; 14:114
Forward-looking statements: This press release contains forward-looking statements that reflect management's current views of future events, including the status of development of the dietary supplement formulations, and the possibility of their approval as a drug in some other countries according to respective governmental authorities. The Company's patented and proprietary dietary supplements, Renadyl™ (for humans) and Azodyl® for cats and dogs with moderate to severe kidney failure (a veterinary formulation licensed to Vetoquinol, http://www.vetoquinolusa.com/) consists of a combination of three specific probiotic microbial strains and chosen prebiotics. Kibow's novel "uremic toxin removal technology" also known as "Enteric Dialysis®" addresses the diffusion of various uremic toxins into the bowel as a consequence of failing kidney function. Kibow Biotech is not a pharmaceutical company. Kibow products are not drugs. Kibow's dietary supplement formulations may not be considered as a treatment or a therapy and are not meant to cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors including but not limited to the possibility that Renadyl™ may not show evidence of clinical activity in each and every individual due to various genetic factors or environmental factors including proper storage, and transportation conditions. Other factors that could cause or contribute to differences in actual results include, but are not limited to, whether or not the Company or any of its collaborators will be able to develop drug pathway using the technologies of the Company, whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators, and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.
Investor & Media Contact:
Terrence O. Tormey, CEO, Kibow Biotech
(610) 353-5130 or Email: email@example.com
SOURCE Kibow Biotech, Inc.